N-benzyl-N-(4-chlorobenzyl)-1-(5-nitrothiophen-2-yl)methanamine | 1242183-51-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 英文名称: N-benzyl-N-(4-chlorobenzyl)-1-(5-nitrothiophen-2-yl)methanamine
• 英文别名: N-[(4-chlorophenyl)methyl]-N-[(5-nitrothiophen-2-yl)methyl]-1-phenylmethanamine
• CAS: 1242183-51-2
• 化学式: C₁₉H₁₇ClN₂O₂S
• 分子量: 372.875
• InChiKey: DLEMDJVIUAYIGD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  25
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.16
• 拓扑面积：
  77.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  5-硝基噻吩-2-甲醛 在 sodium cyanoborohydride 、 溶剂黄146 作用下， 以 乙醇 、 二氯甲烷 、 1,2-二氯乙烷 为溶剂， 反应 16.25h， 生成 N-benzyl-N-(4-chlorobenzyl)-1-(5-nitrothiophen-2-yl)methanamine
  参考文献：
  名称：

  Optimized Chemical Probes for REV-ERBα

  摘要：

  REV-ERB alpha has emerged as an important target for regulation of circadian rhythm and its associated physiology. Herein, we report on the optimization of a series of REV-ERB alpha agonists based on G5K4112 (1) for potency, selectivity, and bioavailability.(1) Potent REV-ERB alpha agonists 4, 10, 16, and 23 are detailed for their ability to suppress BMAL and IL-6 expression from human cells while also demonstrating excellent selectivity over LAR alpha. Amine 4 demonstrated in vivo bioavailability after either iv or oral dosing.

  DOI：

  10.1021/jm400458q

文献信息

• Compositions and methods of treating cardiac hypertrophy and heart failure
  申请人：CASE WESTERN RESERVE UNIVERSITY

  公开号：US11389427B2

  公开（公告）日：2022-07-19

  A method of treating cardiac hypertrophy and/or heart failure in a subject includes administering to the subject a therapeutically effective amount of a REV-ERBα agonist.

  一种治疗受试者心肌肥厚和/或心力衰竭的方法包括向受试者施用治疗有效量的 REV-ERBα 激动剂。
• METHODS OF TREATING HEPATIC FIBROSIS AND ASSOCIATED DISEASES BY REGULATING REV-ERB ACTIVITY
  申请人：The Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Healthcare System

  公开号：EP2931272A1

  公开（公告）日：2015-10-21
• METHODS OF TREATING PORTAL HYPERTENSION
  申请人：The Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Healthcare System

  公开号：EP2931273A1

  公开（公告）日：2015-10-21
• Methods of Treating Portal Hypertension
  申请人：THE CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY D/B/A CAROLINAS HEALTHCARE SYSTEM

  公开号：US20150313871A1

  公开（公告）日：2015-11-05

  The present invention provides methods for treating or preventing portal hypertension comprising administering to a patient in need of such treatment or prevention at least one Rev-erb modulating agent (REMA) in an amount effective to treat or prevent said portal hypertension. The REMA can be SR6452 or a related compound, such as SR9009 or SR9011. The amount of the REMA administered can comprises a quantity sufficient to modulate Rev-erbα expression, activity, and/or subcellular location and/or to inhibit or reverse hepatic stellate cell (HSC) activation and contractility.
• Methods of Treating Hepatic Fibrosis and Associated Diseases by Regulating Rev-ERB Activity
  申请人：The Charlotte-Mecklenburg Hospital Authority d/b/a Carolinas Healthcare System

  公开号：US20150328186A1

  公开（公告）日：2015-11-19

  The present invention is directed to compositions and associated methods for treatment, prevention, amelioration, and/or delaying the onset of hepatic fibrosis and/or associated diseases. The methods preferably involve regulating at least one of Rev-erbα expression, activity, and subcellular localization. In particular, certain embodiments of the present invention relate to compositions and methods of using a Rev-erb-modulating agent (REMA) for the treatment or prevention of hepatic fibrosis and/or associated diseases. Preferably, the amount of a REMA administered comprises a quantity sufficient to modulate at least one of Rev-erbα expression, activity, and subcellular localization and reduce the activation of hepatic stellate cells (HSCs).